Spots Global Cancer Trial Database for anaplastic oligodendroglioma
Every month we try and update this database with for anaplastic oligodendroglioma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | NCT02168270 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Gliosarcoma | ascorbic acid temozolomide quality-of-life... laboratory biom... | 19 Years - | University of Nebraska | |
| Implantable Microdevice In Primary Brain Tumors | NCT04135807 | Grade II Glioma Grade III Gliom... Grade IV Glioma Astrocytoma Oligodendroglio... Anaplastic Astr... Anaplastic Olig... Glioblastoma | Microdevice | 18 Years - | Dana-Farber Cancer Institute | |
| A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | NCT04978727 | Medulloblastoma Glioblastoma Mu... Anaplastic Astr... High-grade Astr... Anaplastic Olig... Anaplastic Epen... Ependymoma Diffuse Intrins... | SurVaxM for pat... SurVaxM for pat... SurVaxM for pat... | 1 Year - 21 Years | Pediatric Brain Tumor Consortium | |
| Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | NCT00362570 | Oligoastrocytom... Anaplastic Olig... | Temozolomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | NCT00303849 | Anaplastic Olig... Anaplastic Olig... Mixed Glioma Oligoastrocytom... | Carboplatin Etoposide Etoposide Phosp... Laboratory Biom... Mannitol Melphalan Quality-of-Life... Sodium Thiosulf... | 18 Years - 75 Years | OHSU Knight Cancer Institute | |
| A Study of Motexafin Gadolinium and Temozolomide for the Treatment of Malignant Gliomas | NCT00080054 | Glioma Glioblastoma Astrocytoma Oligodendroglio... Brain Neoplasm | Motexafin Gadol... | 18 Years - | Pharmacyclics LLC. | |
| Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma | NCT00979173 | Glioma | AC480 | 18 Years - | Duke University | |
| Adaptive Radiotherapy and MRIs Based on Patients With Newly Diagnosed High-Grade Glioma | NCT06108206 | Glioblastoma Anaplastic Astr... Astrocytoma Anaplastic Olig... | Adaptive Radiot... | 18 Years - | Columbia University | |
| Fatigue, Sleep and Cytokines in Primary Brain Tumor (PBT) Patients | NCT00876499 | Brain Cancer | Questionnaire | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma | NCT00539344 | Recurrent or Pr... | ANG1005 | 18 Years - | Angiochem Inc | |
| Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | NCT00062504 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... | Talampanel | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma | NCT03072134 | Glioma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Mu... Astrocytoma, Gr... Astrocytoma, Gr... Brain Cancer | Neural stem cel... | 18 Years - | Northwestern University | |
| INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas | NCT04295759 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... DIPG High-grade Astr... CNS Primary Tum... | INCB7839 | 3 Years - 21 Years | Pediatric Brain Tumor Consortium | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma | NCT02168270 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma Gliosarcoma | ascorbic acid temozolomide quality-of-life... laboratory biom... | 19 Years - | University of Nebraska | |
| Cellular Immunotherapy Study for Brain Cancer | NCT01144247 | Gliomas Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... Glioblastoma Mu... Malignant Menin... | alloreactive CT... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 | NCT01082926 | Anaplastic Astr... Anaplastic Epen... Anaplastic Meni... Anaplastic Olig... Brain Stem Glio... Ependymoblastom... Giant Cell Glio... Glioblastoma Gliosarcoma Grade III Menin... Meningeal Heman... Mixed Glioma Pineal Gland As... Brain Tumor | therapeutic all... aldesleukin laboratory biom... positron emissi... | 18 Years - 70 Years | City of Hope Medical Center | |
| Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I | NCT00671801 | Malignant Gliom... | Irinotecan Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I/II Cabazitaxel for Recurrent Malignant Glioma | NCT01740570 | Brain Cancer | Cabazitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I | NCT00671801 | Malignant Gliom... | Irinotecan Lenalidomide | 18 Years - | M.D. Anderson Cancer Center | |
| Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) | NCT01110876 | Brain Cancer Glioblastoma Mu... | Vorinostat Erlotinib Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma | NCT01095094 | Brain Tumor Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Brain Stem Glio... Giant Cell Glio... Glioblastoma Gliosarcoma Mixed Glioma | ritonavir lopinavir | 18 Years - | Case Comprehensive Cancer Center | |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | NCT02101905 | Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Gliosarcoma Mixed Glioma Recurrent Adult... Recurrent Gliob... | Laboratory Biom... Lapatinib Lapatinib Ditos... Pharmacological... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| (11C)dLop as a Marker of P-Glycoprotein Function in Patients With Gliomas | NCT01281982 | Low Grade Gliom... Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Oligoastrocytom... | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | ||
| Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | NCT00064779 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors | NCT02684058 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Ipon... | Dabrafenib trametinib Carboplatin Vincristine | 12 Months - 17 Years | Novartis | |
| Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms | NCT04541082 | Central Nervous... Glioblastoma Gliosarcoma, Ad... Anaplastic Olig... Anaplastic Astr... Pilocytic Astro... Oligodendroglio... Gliomatosis Cer... Pleomorphic Xan... Anaplastic Pleo... Diffuse Midline... Ependymoma Ependymoma, Ana... Medulloblastoma Teratoid Rhabdo... Neuroectodermal... Neuroectodermal... Anaplastic Meni... Atypical Mening... Choroid Plexus ... Pineal Tumor Diffuse Astrocy... Glial Tumor | ONC206 | 18 Years - | Chimerix | |
| Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | NCT00671970 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Malignant Glioma | NCT00539344 | Recurrent or Pr... | ANG1005 | 18 Years - | Angiochem Inc | |
| Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | NCT01656980 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma | Carmustine tumor resection... | 18 Years - 70 Years | Shandong Lanjin Pharmaceuticals Co.,Ltd | |
| Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma | NCT01656980 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma | Carmustine tumor resection... | 18 Years - 70 Years | Shandong Lanjin Pharmaceuticals Co.,Ltd | |
| PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas | NCT00612651 | Gliosarcoma Glioblastoma Anaplastic Astr... | Temodar and SCH... | 18 Years - | Duke University | |
| Expanded Access to ANG1005 for Individual Patients | NCT02755987 | Anaplastic Astr... Anaplastic Olig... Breast Cancer W... Leptomeningeal ... | ANG1005 | 18 Years - | Angiochem Inc | |
| BIBF 1120 for Recurrent High-Grade Gliomas | NCT01380782 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | BIBF 1120 | 18 Years - | Dana-Farber Cancer Institute | |
| Expanded Access to ANG1005 for Individual Patients | NCT02755987 | Anaplastic Astr... Anaplastic Olig... Breast Cancer W... Leptomeningeal ... | ANG1005 | 18 Years - | Angiochem Inc | |
| Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors | NCT02644291 | Medulloblastoma Astrocytoma, Gr... Glioblastoma Anaplastic Astr... Brain Stem Neop... Oligodendroblas... Anaplastic Olig... Malignant Gliom... | Mebendazole | 1 Year - 21 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | NCT00062504 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... | Talampanel | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma | NCT00064779 | Malignant Gliom... Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Mixed Oligoastr... | IL13-PE38QQR targeted fusion... surgery | 18 Years - | INSYS Therapeutics Inc | |
| Sorafenib in Newly Diagnosed High Grade Glioma | NCT00884416 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | Sorafenib dose ... | 18 Years - | University Hospital, Geneva | |
| A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma | NCT00389090 | Glioma Astrocytoma Oligodendroglio... Oligoastrocytom... | Temozolomide an... | 18 Years - | Keryx / AOI Pharmaceuticals, Inc. | |
| Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma | NCT01637753 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma | Carmustine(BCNU... Surgery | 18 Years - 70 Years | Shandong Lanjin Pharmaceuticals Co.,Ltd | |
| Phase I/II Cabazitaxel for Recurrent Malignant Glioma | NCT01740570 | Brain Cancer | Cabazitaxel | 18 Years - | M.D. Anderson Cancer Center | |
| Antineoplaston Therapy in Treating Children With Brain Tumors | NCT00003458 | Childhood Brain... | Antineoplaston ... | 6 Months - 18 Years | Burzynski Research Institute | |
| Cellular Immunotherapy Study for Brain Cancer | NCT01144247 | Gliomas Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... Glioblastoma Mu... Malignant Menin... | alloreactive CT... | 18 Years - | Jonsson Comprehensive Cancer Center | |
| NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | NCT03353896 | Anaplastic Olig... Oligoastrocytom... Oligodendroglio... | Wear novoTTF-20... Quality-of-Life... | 19 Years - | University of Southern California | |
| Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor | NCT01470794 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | Toca 511 vector Toca FC | 18 Years - 80 Years | Tocagen Inc. | |
| Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | NCT00734864 | Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Glioma | enzyme-inducing... enzyme-inducing... | 18 Years - | Duke University | |
| AZD8055 for Adults With Recurrent Gliomas | NCT01316809 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Malignant Gliom... Brainstem Gliom... | AZD8055 | 18 Years - 99 Years | National Institutes of Health Clinical Center (CC) | |
| Pediatric Long-Term Follow-up and Rollover Study | NCT03975829 | Diffuse Astrocy... Anaplastic Astr... Astrocytoma Oligodendroglio... Anaplastic Olig... Glioblastoma Pilocytic Astro... Giant Cell Astr... Pleomorphic Xan... Anaplastic Pleo... Angiocentric Gl... Chordoid Glioma... Gangliocytoma Ganglioglioma Anaplastic Gang... Dysplastic Gang... Desmoplastic In... Papillary Glion... Rosette-forming... Central Neurocy... Extraventricula... Cerebellar Lipo... Neurofibromatos... | dabrafenib trametinib | 1 Year - | Novartis | |
| Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Recurrent Malignant Glioma | NCT01637753 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Glioblastoma | Carmustine(BCNU... Surgery | 18 Years - 70 Years | Shandong Lanjin Pharmaceuticals Co.,Ltd | |
| Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial | NCT01847235 | Anaplastic Olig... Anaplastic Olig... | Temozolomide | 20 Years - | Seoul National University Hospital | |
| Ph. I Dasatinib/Protracted Temozolomide in Recurrent Malignant Glioma | NCT00734864 | Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Glioma | enzyme-inducing... enzyme-inducing... | 18 Years - | Duke University | |
| A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas | NCT00995007 | Glioblastoma Mu... Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... | ZD6474 (Vandeta... Carboplatin | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial | NCT01847235 | Anaplastic Olig... Anaplastic Olig... | Temozolomide | 20 Years - | Seoul National University Hospital | |
| Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial | NCT01847235 | Anaplastic Olig... Anaplastic Olig... | Temozolomide | 20 Years - | Seoul National University Hospital | |
| Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma | NCT00362570 | Oligoastrocytom... Anaplastic Olig... | Temozolomide | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Viral Therapy in Treating Patients With Recurrent Glioblastoma Multiforme | NCT00390299 | Anaplastic Astr... Anaplastic Olig... Mixed Glioma Recurrent Gliob... | Carcinoembryoni... Laboratory Biom... Therapeutic Con... | 18 Years - | Mayo Clinic | |
| Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas | NCT00062504 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... | Talampanel | 18 Years - | Teva Branded Pharmaceutical Products R&D, Inc. | |
| Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas | NCT01966809 | Brain Tumor, Re... | Photofrin photo... | 18 Years - | Medical College of Wisconsin | |
| Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies | NCT04047264 | Anaplastic Astr... Anaplastic Olig... Diffuse Astrocy... Diffuse Glioma Glioblastoma Metastatic Mali... Oligodendroglio... | Microdialysis | 18 Years - | Mayo Clinic | |
| Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor | NCT01985256 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | Toca 511 Toca FC | 18 Years - 80 Years | Tocagen Inc. | |
| Expanded Access to ANG1005 for Individual Patients | NCT02755987 | Anaplastic Astr... Anaplastic Olig... Breast Cancer W... Leptomeningeal ... | ANG1005 | 18 Years - | Angiochem Inc | |
| Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors | NCT00303849 | Anaplastic Olig... Anaplastic Olig... Mixed Glioma Oligoastrocytom... | Carboplatin Etoposide Etoposide Phosp... Laboratory Biom... Mannitol Melphalan Quality-of-Life... Sodium Thiosulf... | 18 Years - 75 Years | OHSU Knight Cancer Institute | |
| Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | NCT00671970 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma | NCT03353896 | Anaplastic Olig... Oligoastrocytom... Oligodendroglio... | Wear novoTTF-20... Quality-of-Life... | 19 Years - | University of Southern California | |
| A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511 | NCT04327011 | Glioblastoma Mu... Astrocytoma Gliomas, Malign... | Toca 511 vector Toca FC • Flucy... | 18 Years - | Tocagen Inc. | |
| Ph I SU011248 + Irinotecan in Treatment of Pts w MG | NCT00611728 | Glioblastoma | SU011248 & Irin... | 18 Years - | Duke University | |
| Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma | NCT02101905 | Anaplastic Astr... Anaplastic Epen... Anaplastic Olig... Gliosarcoma Mixed Glioma Recurrent Adult... Recurrent Gliob... | Laboratory Biom... Lapatinib Lapatinib Ditos... Pharmacological... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas | NCT04623931 | Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Diffuse Astrocy... Glioblastoma Oligoastrocytom... Oligodendroglio... WHO Grade II Gl... WHO Grade III G... | Quality-of-Life... Questionnaire A... Radiation Thera... Temozolomide | 18 Years - | M.D. Anderson Cancer Center | |
| Study of Capecitabine to Treat Recurrent High Grade Gliomas | NCT00717197 | Malignant Gliom... | Capecitabine | 18 Years - | University of Florida | |
| Pharmacokinetics (PK) Study of AC480 for Recurrent Glioma | NCT00979173 | Glioma | AC480 | 18 Years - | Duke University | |
| Phase I/II Trial of AXL1717 in the Treatment of Recurrent Malignant Astrocytomas | NCT01721577 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... Anaplastic Epen... | AXL1717 | 18 Years - | Rush University Medical Center | |
| Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) | NCT00671970 | Glioblastoma Gliosarcoma | Bevacizumab and... | 18 Years - | Duke University | |
| Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | NCT00667394 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Mixe... | Bevacizumab MLN-518 (Tandut... Quality-of-life... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Examination of Changes on Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) in Patients Who Receive Gliadel Wafers During Initial Surgery for Glioblastoma Multiforme. Response or Failure to Gliadel Wafers for Subjects With Glioblastoma Multiforme. | NCT00645385 | Glioblastoma Mu... Anaplastic Astr... Anaplastic Olig... | MRS Spectroscop... | 18 Years - 85 Years | Weill Medical College of Cornell University | |
| A Phase I Trial of Nanoliposomal CPT-11 (NL CPT-11) in Patients With Recurrent High-Grade Gliomas | NCT00734682 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... | Nanoliposomal C... | 18 Years - | University of California, San Francisco | |
| Sorafenib in Newly Diagnosed High Grade Glioma | NCT00884416 | Glioblastoma Gliosarcoma Anaplastic Astr... Anaplastic Olig... Anaplastic Olig... | Sorafenib dose ... | 18 Years - | University Hospital, Geneva | |
| Antineoplaston Therapy in Treating Children With Brain Tumors | NCT00003458 | Childhood Brain... | Antineoplaston ... | 6 Months - 18 Years | Burzynski Research Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
